Skip to content

NASDAQ · mid · thesis board

JANX Janux Therapeutics

TRACTr T-cell engager (JANX007) for prostate cancer

View race

Thesis

Editorial summary — not a primary filing

Tumor-activated T-cell engagers; JANX007 in prostate is the near-term binary.

Next gate

2026-10-28Company-guidedPh2 readout

JANX007 prostate update

76 days · Company: Company guidance

Survive-to-Event

ok

Cash covers the next gate with ~12 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~452d)100%
Days to gate (76d)17%
Show math

$520M cash ÷ $35M/mo burn ≈ 452 days. Source: curated SEC quarter figures.

Cash $520M as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
AZNApprovedokEXELApprovedokPFEApprovedok

Risks

  • Early clinical risk
  • CRS / safety
  • Crowded prostate field
  • Dilution

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT05519449as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01